Preventing clinical deterioration in the course of schizophrenia: The potential for neuroprotection

Journal of Clinical Psychiatry

Volumn 67, Issue 6, 2006, Pages 983-990

  Lieberman, Jeffrey A ^a   Jarskog, L Fredrik ^b   Malaspina, Dolores ^a  

^a New York State Psychiatric Institute ^*  (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; OLANZAPINE;

CONFERENCE PAPER; DEGENERATIVE DISEASE; DETERIORATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; HISTORY; HUMAN; HYPOTHESIS; NERVE CELL DIFFERENTIATION; NEUROIMAGING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTHUMOUS CARE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL CARE; RISK FACTOR; SCHIZOPHRENIA;

EID: 33745910566     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v67n0616     Document Type: Conference Paper

References (20)

1. Kraepelin E. Dementia Praecox and Paraphrenia. Huntington, NY: RE Krieger; 1971
2. Lieberman J, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884-897
3. Thompson PM, Vidal C, Gochman P, et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U S A 2001;98:11650-11655
4. Rapoport JL, Addington AM, Frangou S, et al. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005;10:434-449
5. Gottesman II, Shields J. Schizophrenia: The Epigenetic Puzzle. Cambridge, UK: Cambridge University Press; 1982
6. Malaspina D, Sohler NL, Susser E; Interaction of genes and prenatal exposures in schizophrenia. In: Susser E, Brown AS, Gorman JM, eds. Prenatal Exposures in Schizophrenia. Arlington, Va: American Psychiatric Press, Inc; 1999:35-61
7. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291:1304-1351
8. Malaspina D. Paternal factors and schizophrenia risk: de novo mutations and imprinting. Schizophr Bull 2001;27:379-393
9. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005;19:187-194
10. Corcoran C, Walker E, Huot R, et al. The stress cascade and schizophrenia: etiology and onset. Schizophr Bull 2003;29:671-693
11. Corcoran C, Malaspina D. Traumatic brain injury and schizophrenia risk. Int J Ment Health 2001;3:17-33
12. Harkavy-Friedman J, Kimhy D, Goetz R, et al. Course of illness in schizophrenia: is there a relationship with premorbid social adjustment? [abstract] Schizophr Bull 2005;31:201
13. Pantelis C, Velakoulis D, McGorry PD. et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003;361:281-288
14. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007
15. Jarskog LF, Gilmore JH, Selinger ES, et al. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol Psychiatry 2000;48:614-650
16. Jarskog LF, Selinger ES, Lieberman JA, et al. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry 2004;161:109-115
17. Rajkowska G, Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 1998;55:215-224
18. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 2000;57:67-73
19. Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005;62:361-370
20. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000;26:119-136